Beyond the Scale: How Elevate Now Is Transforming Weight Loss for Patients with PMOS, Insulin Resistance, and Diabetes
50,000-patient study reports 11.8% average weight loss at 12 months August, 2026: For millions of Indians living with PMOS, insulin resistance or Type 2 diabetes, losing weight is far more complex...
50,000-patient study reports 11.8% average weight loss at 12 months
August, 2026: For millions of Indians living with PMOS, insulin resistance or Type 2 diabetes, losing weight is far more complex than simply eating less and exercising more. Many spend years cycling through restrictive diets, intense workout routines and conventional weight-loss programmes, only to see little or no lasting progress. The reason is simple: these conditions fundamentally alter the body’s metabolism, making sustainable weight loss difficult when the underlying biological and hormonal drivers are left untreated.
New clinical outcomes data from Elevate Now, India’s largest data-backed metabolic health programme, suggests that meaningful and sustainable weight loss is possible even among patients traditionally considered the hardest to treat.
Drawing on outcomes from more than 50,000 patient journeys, Elevate Now’s latest Clinical Excellence Report found that patients achieved an average body weight reduction of 11.8% over 12 months, while the highest-performing patients exceeded 20% weight loss.
Key Findings from Elevate Now’s Clinical Outcomes Report
- 50,000+ patients served
- 11.8% average weight loss at 12 months
- 20%+ weight loss among top-performing patients
- 83% of patients presented with insulin resistance
- 12.1% average weight loss among PMOS patients
- 11.45% average weight loss among Type 2 Diabetes patients
- Over 95,000 consultations delivered
- More than 75,000 blood tests processed
The significance of these outcomes becomes clearer when viewed against the profile of patients entering the programme. According to the report, 83% present with insulin resistance, nearly two-thirds have elevated inflammation markers, 39.4% have dyslipidemia, 25.7% are prediabetic and more than one in five are already living with Type 2 Diabetes.
Despite these challenges, Elevate Now’s data shows consistent double-digit weight loss across major metabolic conditions. Patients with PMOS achieved an average weight loss of 12.1% at 12 months, while those with Type 2 Diabetes, hypothyroidism, fatty liver disease and hypertension recorded average reductions between 11% and 12%. Among the highest-performing patients, weight loss ranged from 19% to 21% across cohorts, approaching outcomes traditionally associated with bariatric surgery.
The findings challenge the long-held belief that conditions such as PMOS, diabetes and thyroid disorders make meaningful weight loss nearly impossible. Instead, they suggest that when underlying metabolic factors are identified and addressed, these conditions need not become lifelong barriers to better health.
Commenting on the findings, Suryansh Kumar, Founder & CEO, Elevate Now, said: “One of the biggest misconceptions in obesity care is that weight loss failure is a motivation problem. What we see every day is that many patients are fighting biology they don’t fully understand—insulin resistance, chronic inflammation, hormonal dysfunction and metabolic disease. When those underlying barriers are identified and treated, outcomes that once seemed impossible become achievable. At Elevate Now, our goal has never been to help people lose weight for a few months; it has been to create sustainable outcomes built around each patient’s biology. When treatment becomes personalised and medically guided, weight loss stops being a question of willpower and becomes a question of solving the right problem.”
Today, Elevate Now serves more than 50,000 patients across India through a combination of medical consultations, diagnostics, personalised nutrition, fitness guidance and behavioural coaching. With over 95,000 consultations delivered and 75,000+ blood tests processed, the company has built one of India’s largest real-world metabolic health datasets, helping continuously refine its clinical protocols and patient outcomes.
As obesity and metabolic disorders continue to rise across India, the findings offer a hopeful message: conditions such as insulin resistance, PMOS, diabetes and hypothyroidism may make weight loss more challenging, but they do not make it impossible. Increasingly, Elevate Now’s data suggests that sustainable weight loss begins not with trying harder, but with understanding the biology behind weight gain and treating it accordingly.
